BIO Submits Comments to HHS Regarding the Proposed Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) Charter
<div>
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on</div>
<div>
the proposed changes to the Medicare Evidence Development and Coverage Advisory</div>
<div>
Committee’s (MEDCAC’s) charter, which were released on August 1, 2014.</div>
August 29, 2014
BY ELECTRONIC DELIVERY
Sylvia M. Burwell
Secretary
Department of Health and Human Services
Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201
RE: Proposed Medicare Evidence Development and Coverage Advisory Committee
(MEDCAC) Charter
Dear Secretary Burwell:
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on
the proposed changes to the Medicare Evidence Development and Coverage Advisory
Committee’s (MEDCAC’s) charter, which were released on August 1, 2014.1 BIO represents
more than 1,000 biotechnology companies, state biotechnology centers, academic
institutions, and related organizations both in the United States and abroad. BIO members
are critical contributors to the research and development of innovative health care,
agricultural, industrial, and environmental biotechnology products.
